Candriam S.C.A. cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 113,607 shares of the medical equipment provider's stock after selling 4,400 shares during the period. Candriam S.C.A. owned about 0.16% of Lantheus worth $10,163,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the third quarter valued at approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the 4th quarter worth approximately $27,000. UMB Bank n.a. boosted its stake in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares in the last quarter. RiverPark Advisors LLC bought a new stake in Lantheus in the third quarter valued at $74,000. Finally, Farther Finance Advisors LLC raised its stake in Lantheus by 226.7% during the third quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider's stock worth $83,000 after acquiring an additional 526 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently commented on LNTH. JMP Securities restated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $132.86.
View Our Latest Research Report on LNTH
Shares of NASDAQ LNTH traded up $6.11 during midday trading on Friday, hitting $106.34. The stock had a trading volume of 1,369,851 shares, compared to its average volume of 921,738. Lantheus Holdings, Inc. has a fifty-two week low of $56.44 and a fifty-two week high of $126.89. The firm has a market cap of $7.28 billion, a P/E ratio of 17.69 and a beta of 0.38. The company's 50-day simple moving average is $90.71 and its 200 day simple moving average is $96.85.
Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.
In other Lantheus news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Before you consider Lantheus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantheus wasn't on the list.
While Lantheus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.